...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: BIO Investor Forum, Oct 22-23

BIO Investor Forum. October 22 - 23, 2019, San Francisco, California

Resverlogix and Zenith both on the presenting companies list for Wednesday October 23.

https://www.bio.org/events/bio-investor-forum

Share
New Message
Please login to post a reply